Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B | $1.60B |
| Cost of Revenue | N/A | N/A | N/A | N/A | $230.84M | N/A | N/A | N/A |
| Gross Profit | $2.26B | $2.35B | $2.24B | $2.29B | $1.89B | $1.81B | $1.79B | $1.60B |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 89.12% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $971.13M | $862.40M | $1.93B | $858.75M | $296.12M | $-808.92M | $430.45M | $658.24M |
| Operating Income | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B | $2.62B | $1.36B | $939.69M |
| Operating Margin | 57.10% | 63.37% | 13.73% | 62.49% | 75.17% | 144.59% | 76.02% | 58.81% |
| Net Income | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M | $2.35B | $1.38B | $1.21B |
| Net Margin | 37.95% | 48.20% | 1.91% | 27.07% | 45.94% | 129.45% | 76.76% | 75.72% |
| EPS (Basic) | $1.92 | $2.54 | $0.10 | $1.49 | $2.60 | $6.42 | $2.27 | $1.99 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |